Bio-Imaging Technologies Signs Collaborative Agreement with LUMC/LKEB in Netherlands to Develop Quantitative CTA Software.

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ/NMS: BITI) today announced that it has entered into a collaborative agreement with Division of Image Processing ("LKEB") at the Department of Radiology at Leiden University Medical Center ("LUMC"), Leiden, The Netherlands. LKEB will develop clinical software for the quantitative analysis of CT angiography ("CTA") for Bio-Imaging's exclusive use in clinical trials. The CTA software will be tailored to the needs of Bio-Imaging's use of the software within the highly regulated clinical trials industry, including the need for comprehensive reporting and complete audit trails.

Mark L. Weinstein, President and Chief Executive Officer of Bio-Imaging, said, "Bio-Imaging has a long-standing relationship with LKEB and the Leiden University Medical Center. Prof. Johan H.C. Reiber, Ph.D., is the Director of LKEB, Department of Radiology, and a member of our Scientific Advisory Board. This collaborative agreement further strengthens the relationship between Bio-Imaging and LKEB and continues our strategy of introducing new image analysis services and expanding our therapeutic expertise in the cardiovascular area."

Prof. Reiber, Director of LKEB stated, "This agreement will ensure that Bio-Imaging remains on the cutting edge of imaging technology. In the past few years LKEB has developed several useful tools for quantitative analysis: the segmentation of vessel trees and vessel segments after the positioning of seed points, the quantitative analysis (diameter, area and stenosis measurements) of vessel segments, and quantitative analysis of in-stent restenosis in peripheral vessels (which was specifically developed for an in-stent restenosis study at Bio-Imaging). We believe the software engineers at LKEB are among the best in the world and that their continued efforts will result in an elegant and useful package."

Colin Miller, Senior Vice President of Medical Affairs, commented, "This agreement covers a three phase development plan that begins with quantitative analysis of large peripheral vessels and includes the refinement of our current in-stent restenosis program. With such an agreement, Bio-Imaging continues to ensure that the in-house software we utilize is of the optimum standard enabling us to continue to provide the high level of service and data quality for which we are known. Furthermore, this collaboration, with a world-renowned organization, allows Bio-Imaging to be at the leading edge of CTA in clinical trials."

John Blank, Managing Director of Bio-Imaging's European Operations, Leiden, remarked, "The location of our two organizations in Leiden facilitates the collaborative development of new quantitative imaging techniques. We value the close operational relationship with the Department of Radiology and the Division of Image Processing (LKEB) at Leiden University Medical Center and look forward to working with the outstanding team at LKEB on this project."

About Bio-Imaging

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands, and business offices in Massachusetts, the United Kingdom and Germany. Through its CapMed division, Bio-Imaging provides the Personal HealthKey(TM) technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.

About LKEB

Leiden University's Division of Image Processing, also known as the Laboratory for Clinical and Experimental Image processing (Dutch abbreviation: LKEB), is a division of the Department of Radiology of Leiden University Medical Center. LKEB is involved with the research, implementation and validation of image processing approaches which allow the objective and reproducible assessment of objects in medical images using automated segmentation techniques. For further information, visit LKEB's website at www.lumc.nl.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the Company's financial projections, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.